J. Safra Sarasin Holding AG Sells 44,836 Shares of DexCom, Inc. (NASDAQ:DXCM)

J. Safra Sarasin Holding AG cut its stake in DexCom, Inc. (NASDAQ:DXCM) by 55.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,575 shares of the medical device company’s stock after selling 44,836 shares during the quarter. J. Safra Sarasin Holding AG’s holdings in DexCom were worth $2,767,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Versant Capital Management Inc bought a new position in DexCom in the 4th quarter valued at about $25,000. Private Trust Co. NA lifted its holdings in DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after purchasing an additional 245 shares during the last quarter. TD Private Client Wealth LLC boosted its stake in DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 167 shares during the period. Larson Financial Group LLC grew its holdings in DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after buying an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC bought a new position in DexCom during the 4th quarter worth $38,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Transactions at DexCom

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the transaction, the chief executive officer now directly owns 372,029 shares of the company’s stock, valued at $26,183,401.02. This trade represents a 8.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 105,009 shares of company stock valued at $8,044,178. Company insiders own 0.32% of the company’s stock.

DexCom Trading Down 3.6 %

NASDAQ DXCM opened at $66.11 on Tuesday. The company has a market capitalization of $25.92 billion, a price-to-earnings ratio of 46.23, a PEG ratio of 2.30 and a beta of 1.50. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $139.24. The stock’s 50-day simple moving average is $74.62 and its two-hundred day simple moving average is $76.74.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Mizuho initiated coverage on shares of DexCom in a research note on Thursday, April 10th. They issued an “outperform” rating and a $85.00 price target on the stock. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and lifted their price target for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Wells Fargo & Company restated an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Finally, Cfra Research raised DexCom to a “hold” rating in a research note on Friday, March 21st. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $99.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.